Alarmed by Ozempic and Wegovy’s popularity, insurers wage battle

Patients are bracing for “D-Day,” the date their insurance coverage firms will cease overlaying the medication. Docs are getting letters from insurance coverage investigators discouraging new prescriptions. And pharmacies are being advised by insurers to verify for a particular analysis when filling prescriptions.

It’s a cost on all fronts by insurance coverage firms to include the spiraling prices of a brand new class of weight loss-inducing medication, the GLP-1s.

A few of these therapies — like Novo Nordisk’s Wegovy — are accredited for weight problems, whereas others — like Novo’s Ozempic and Eli Lilly’s Mounjaro — are accredited for diabetes, however all of them make use of comparable mechanisms and have exploded in demand for his or her means to curb urge for food and reduce vital quantities of weight.